K
Kim A. Eagle
Researcher at University of Michigan
Publications - 852
Citations - 85694
Kim A. Eagle is an academic researcher from University of Michigan. The author has contributed to research in topics: Aortic dissection & Myocardial infarction. The author has an hindex of 129, co-authored 823 publications receiving 75160 citations. Previous affiliations of Kim A. Eagle include University of Wisconsin Hospital and Clinics & Spaulding Rehabilitation Hospital.
Papers
More filters
Journal ArticleDOI
Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
TL;DR: The evidence for β-blocker therapy to reduce morbidity and mortality in Marfan syndrome is limited to a single small, prospective randomized and nonblinded clinical trial, suggesting that this study was underpowered to assess adverse aortic outcomes.
Journal ArticleDOI
NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.
Payal Kohli,Ph. Gabriel Steg,Christopher P. Cannon,Sidney C. Smith,Kim A. Eagle,E. Magnus Ohman,Mark J. Alberts,Elaine B. Hoffman,Jianping Guo,Tabassome Simon,Emmanuel Sorbets,Shinya Goto,Deepak L. Bhatt,Deepak L. Bhatt +13 more
TL;DR: Among patients with stable atherothrombosis, NSAID use is associated with a higher risk of myocardial infarction, stroke, and hospitalizations for both ischemia and heart failure.
Journal ArticleDOI
Perioperative Mischief: The Price of Academic Misconduct
Vineet Chopra,Kim A. Eagle +1 more
TL;DR: This brief review reiterates and emphasizes basic principles about the indications and administration of perioperative beta blockade and presents strategies to prevent such events in the future.
Journal ArticleDOI
Concordance of preoperative clinical risk with angiographic severity of coronary artery disease in patients undergoing vascular surgery
TL;DR: By reliably identifying a large proportion of patients with a low likelihood of significant stenosis, these prediction rules can help to substantially reduce healthcare costs associated with preoperative cardiac risk assessment for noncardiac surgery.
Journal ArticleDOI
Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis
Boris Hansel,Boris Hansel,Ronan Roussel,Ronan Roussel,Y Elbez,Y Elbez,Michel Marre,Michel Marre,Michel Krempf,Yasuo Ikeda,Kim A. Eagle,Moses Elisaf,Deepak L. Bhatt,Ph. Gabriel Steg +13 more
TL;DR: An obesity paradox was observed in both primary and secondary CV prevention patients, suggesting that the intensity of use of evidence-based preventive medications does not account for the paradoxical CV protection associated with obesity.